First Patient Treated in Rakuten Medicals Global Phase 3 Trial in India

Rakuten Medical Inc. a global biotechnology company developing and commercializing precision cell targeting therapies based on its proprietary Alluminox platform today announced that the first patient in India received Alluminox treatment photoimmunotherapy using ASP1929 in August 2023 under Rakuten Medicals global.

Related Keywords

Taiwan ,United States ,Switzerland ,Japan ,France ,Mumbai ,Maharashtra ,India ,Japanese ,Hisataka Kobayashi ,Subramania Iyer ,Research Centre Kochi ,Amrita Institute Of Medical Sciences ,National Cancer Institute ,National Conference Of Foundation ,International Agency For Research On Cancer ,Rakuten Medical Inc ,Drug Administration ,Japanese Ministry Of Health ,Rakuten Medical ,National Conference ,Neck Oncology ,Amrita Institute ,Medical Sciences ,Research Centre ,Global Cancer Observatory ,International Agency ,Neck Cancer Burden ,Intj Head ,Neck Surg ,About Rakuten Medical ,Fast Track ,Japanese Ministry ,Sakigake Designation System ,Conditional Early Approval ,Rakuten Medical Inc Global Biotechnology Company Commercializing Precision Cell Targeting Therapies Alluminox Treatment Photoimmunotherapy Asp1929 Recurrent Head Cancer Neck Asp1929301 Study Clinicaltrials Gov Identifier Nct03769506 Institutions Oncology Surgery Radiation Chemotherapy Subramania Iyerk Amrita Institute Sciences Research Centre Hisataka Kobayashi Tumor Microenvironment ,